Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development - HUB Organoids Holdings B.V. revolutionizes pre-clinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency - HubOrganoids.nl
HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development

 

PRZOOM - /newswire/ - San Antonio, TX, United States, 2024/05/15 - HUB Organoids Holdings B.V. revolutionizes pre-clinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency - HubOrganoids.nl.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan recently researched the organoids landscape and, based on its findings, recognizes HUB Organoids B.V (HUB) with the 2024 Global Technology Innovation Leadership Award. HUB is a global leader in patient-derived organoid (PDO) technology that enables drug developers to identify and validate clinical candidates in a patient-relevant in vitro system.

As a pioneer in organoid technology, HUB offers transformative solutions to the pharmaceutical industry for more effective, faster, and ethical drug development. HUB develops disruptive PDOs that accurately replicate human drug responses compared to animal models and cell lines, greatly increasing the value and impact of drug development programs.

This award recognizes HUB at the forefront of innovation and growth in the field of organoid technology, continuously improving its offerings to meet the dynamic needs of drug developers and providing state-of-the-arts solutions. The company utilizes groundbreaking stem cell technology and expertise in various fields, such as high throughput screening, 3D cell culture, high content imaging, molecular biology, genetic engineering, and organoid sorting, to bridge the gap between laboratory research and clinical applications.

“Frost & Sullivan identifies HUB’s epithelial tissue-based technology as groundbreaking and innovative. Its strong intellectual property portfolio, covering multiple disease areas (e.g., oncology and immuno-oncology, infectious- and genetic diseases, and toxicology) upholds its pioneering technology, adding value relative to its growth potential, thus securing a competitive advantage,” said Unmesh Lal, Global Director of Healthcare & Life Sciences at Frost & Sullivan.

‘HUB is delighted to receive this recognition by the global experts of Frost & Sullivan,” said Robert Vries, HUB CEO.”For more than a decade we have worked on the establishment of our technology to improve patients care and support our partners. This award is a fantastic confirmation that our team is changing drug development.”

HUB meticulously crafts its targeted marketing campaigns to highlight specific applications of organoid technology to accelerate and improve drug testing. The company’s proactive approach to using digital platforms for outreach has played a crucial role in demystifying complex scientific processes and showcasing the tangible benefits of organoids in drug discovery and development.

“By promoting the key advantages of using organoids for drug discovery and development, HUB succeeded in raising awareness and increasing its brand equity. The company is active on social media and launches targeted marketing campaigns frequently,” said Riana Barnard, Best Practice Research Analyst at Frost & Sullivan. “Furthermore, its subject matter experts participate in regular thought leadership opportunities to educate existing and potential clients. These practices demonstrate the value of HUB’s products and services.”

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Hub Organoids B.V. (HUB)

HUB Organoids (huborganoids.nl) is the global leader in the field of adult stem cell-derived organoids. HUB Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug development services using its living organoid biobanks.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
HUB Organoids B.V. | Frost & Sullivan
Contact: Tarini Singh - Frost.com 
+91 99 53764546 tarini.singh[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ipsen’s Iqirvo® Receives U.S. FDA Accelerated Approval as A First-in-class PPAR Treatment for Primary Biliary Cholangitis
Ipsen Presents Long-term Elafibranor Efficacy and Itch-related Quality of Life Data in Patients with Primary Biliary Cholangitis
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations
Ipsen and Skyhawk Therapeutics Announce RNA Targeting Research Collaboration in Rare Neurological Diseases
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer At AACR 2024
Bruker Showcases High-Performance Solutions at Analytica 2024 for Research and Analysis in Applied, Industrial and Biopharma Laboratories
STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests
ONO Implements Oracle's CTMS for Global Centralized Management of Clinical Trials
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Bruker Completes Acquisition of Optical Cell Imaging Company Phasefocus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.

Visit  JobsWare.com







 
  ©2005-2024 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today